Sweden's Ascelia Pharma Q4 operating loss narrows to SEK 15.8 mln

Ascelia Pharma AB

05/02/2026 06:40

Overview

Swedish biotech firm's Q4 operating loss narrows to SEK 15.8 mln

Earnings per share for Q4 improved to SEK -0.13 from SEK -0.29

FDA accepted Orviglance NDA, decision expected by July 2026

Outlook

Company expects FDA decision on Orviglance by 3 July 2026

Ascelia Pharma has cash runway into Q4 2026

Company sees strong strategic interest from potential partners

Result Drivers

FDA ACCEPTANCE - FDA accepted Orviglance NDA for review, aiming for decision by July 2026, marking a critical step in drug development

CASH RUNWAY - Directed share issue in September 2025 raised SEK 30 mln, extending cash runway into Q4 2026

PARTNERSHIP PROGRESS - Ongoing partnering discussions gained momentum with regulatory timeline established for Orviglance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-SEK 0.13
Q4 Cash Flow From Operations
-SEK 21.70 mln
Q4 EBIT
-SEK 15.80 mln


Analyst Coverage

Wall Street's median 12-month price target for Ascelia Pharma AB is SEK8.00, about 207.7% above its February 4 closing price of SEK2.60

Press Release: ID:nMFN9m34lD

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)